Therapeutic Antibodies in Stroke

Translational Stroke Research

Volumn 4, Issue 5, 2013, Pages 477-483

  Yu, Chye Yun ^a   Ng, Gandi ^a   Liao, Ping ^a  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Antibody; Immunotherapy; Stroke

Indexed keywords

ADALIMUMAB; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CD18 ANTIBODY; CD18 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 ANTIBODY; ENLIMOMAB; FAS LIGAND; GLUTAMATE RECEPTOR ANTAGONIST; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; L SELECTIN; L SELECTIN ANTIBODY; MONOCLONAL ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUTRALIZING ANTIBODY; NOGO 66 RECEPTOR; NOGO A ANTIBODY; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; PADGEM PROTEIN; PROTEIN ANTIBODY; PROTEIN NOGO A; RECOMBINANT PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL INFILTRATION; CEREBROVASCULAR ACCIDENT; CROHN DISEASE; DETERIORATION; DIARRHEA; DYSPNEA; FATIGUE; FEVER; HEADACHE; HEART ARREST; HEART INFARCTION; HEART PALPITATION; HOARSENESS; HUMAN; IMMUNOTHERAPY; LEUKOCYTE FUNCTION; LUNG EDEMA; LUNG EMBOLISM; MALAISE; MENINGITIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NAUSEA; NERVE CELL PLASTICITY; PASSIVE IMMUNIZATION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SUBUNIT; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINAL CORD INJURY; STROKE RELATED DETERIORATION; TISSUE INJURY; TREATMENT FAILURE; VEIN THROMBOSIS;

ANTIBODY; IMMUNOTHERAPY; STROKE;

ANIMALS; ANTIBODIES; BIOMEDICAL RESEARCH; CELL ADHESION MOLECULES; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MYELIN PROTEINS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84884907132     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0281-2     Document Type: Review

References (73)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480: 480-9.
2. Iorio R, Lennon VA. Neural antigen-specific autoimmune disorders. Immunol Rev. 2012;248: 104-21.
3. Villoslada P, Moreno B, Melero I, Pablos JL, Martino G, Uccelli A, et al. Immunotherapy for neurological diseases. Clin Immunol. 2008;128: 294-305.
4. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17: 796-808.
5. Donnan GA, Davis SM. Stroke: expanded indications for stroke thrombolysis-what next? Nat Rev Neurol. 2012;8: 482-3.
6. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 2006;7: 617-27.
7. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012;8: 624-34.
8. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature. 2000;403: 439-44.
9. Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001;409: 341-6.
10. Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron. 1988;1: 85-96.
11. Seymour AB, Andrews EM, Tsai SY, Markus TM, Bollnow MR, Brenneman MM, et al. Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats. J Cereb Blood Flow Metab. 2005;25: 1366-75.
12. Tsai SY, Markus TM, Andrews EM, Cheatwood JL, Emerick AJ, Mir AK, et al. Intrathecal treatment with anti-Nogo-A antibody improves functional recovery in adult rats after stroke. Exp Brain Res. 2007;182: 261-6.
13. Tsai SY, Papadopoulos CM, Schwab ME, Kartje GL. Delayed anti-Nogo-a therapy improves function after chronic stroke in adult rats. Stroke. 2011;42: 186-90.
14. Papadopoulos CM, Tsai SY, Cheatwood JL, Bollnow MR, Kolb BE, Schwab ME, et al. Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb Cortex. 2006;16: 529-36.
15. Papadopoulos CM, Tsai SY, Alsbiei T, O'Brien TE, Schwab ME, Kartje GL. Functional recovery and neuroanatomical plasticity following middle cerebral artery occlusion and IN-1 antibody treatment in the adult rat. Ann Neurol. 2002;51: 433-41.
16. Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, et al. Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J Cereb Blood Flow Metab. 2003;23: 154-65.
17. Gillani RL, Tsai SY, Wallace DG, O'Brien TE, Arhebamen E, Tole M, et al. Cognitive recovery in the aged rat after stroke and anti-Nogo-A immunotherapy. Behav Brain Res. 2010;208: 415-24.
18. Ma J, Tian WM, Hou SP, Xu QY, Spector M, Cui FZ. An experimental test of stroke recovery by implanting a hyaluronic acid hydrogel carrying a Nogo receptor antibody in a rat model. Biomed Mater. 2007;2: 233-40.
19. Kilic E, ElAli A, Kilic U, Guo Z, Ugur M, Uslu U, et al. Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J Cereb Blood Flow Metab. 2010;30: 969-84.
20. Irving EA, Vinson M, Rosin C, Roberts JC, Chapman DM, Facci L, et al. Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? J Cereb Blood Flow Metab. 2005;25: 98-107.
21. Derfuss T, Meinl E. Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment? Curr Opin Neurol. 2012;25: 231-8.
22. Frenkel D, Huang Z, Maron R, Koldzic DN, Hancock WW, Moskowitz MA, et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol. 2003;171: 6549-55.
23. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333: 1581-7.
24. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7: 59-64.
25. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science. 2000;287: 1453-60.
26. Benchenane K, Castel H, Boulouard M, Bluthe R, Fernandez-Monreal M, Roussel BD, et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci. 2007;120: 578-85.
27. Macrez R, Obiang P, Gauberti M, Roussel B, Baron A, Parcq J, et al. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke. 2011;42: 2315-22.
28. Macrez R, Bezin L, Le Mauff B, Ali C, Vivien D. Functional occurrence of the interaction of tissue plasminogen activator with the NR1 subunit of N-methyl-d-aspartate receptors during stroke. Stroke. 2010;41: 2950-5.
29. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006;6: 53-60.
30. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10: 63-74.
31. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30: 5866-75.
32. Matsuo Y, Kihara T, Ikeda M, Ninomiya M, Onodera H, Kogure K. Role of neutrophils in radical production during ischemia and reperfusion of the rat brain: effect of neutrophil depletion on extracellular ascorbyl radical formation. J Cereb Blood Flow Metab. 1995;15: 941-7.
33. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke. 1994;25: 1469-75.
34. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C. The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res. 1998;785: 207-14.
35. Suzuki H, Abe K, Tojo SJ, Kitagawa H, Kimura K, Mizugaki M, et al. Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. Neurol Res. 1999;21: 269-76.
36. Suzuki H, Hayashi T, Tojo SJ, Kitagawa H, Kimura K, Mizugaki M, et al. Anti-P-selectin antibody attenuates rat brain ischemic injury. Neurosci Lett. 1999;265: 163-6.
37. Huang J, Choudhri TF, Winfree CJ, McTaggart RA, Kiss S, Mocco J, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke. 2000;31: 3047-53.
38. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab. 2009;29: 606-20.
39. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 2002;33: 2156-63.
40. Yenari MA, Sun GH, Kunis DM, Onley D, Vexler V. L-selectin inhibition does not reduce injury in a rabbit model of transient focal cerebral ischemia. Neurol Res. 2001;23: 72-8.
41. Bednar MM, Gross CE, Russell SR, Fuller SP, Ellenberger CL, Schindler E, et al. Humanized anti-L-selectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke. Neurol Res. 1998;20: 403-8.
42. Rieckmann P, Nunke K, Burchhardt M, Albrecht M, Wiltfang J, Ulrich M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol. 1993;47: 133-40.
43. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest. 1989;83: 2008-17.
44. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke. 2002;33: 2115-22.
45. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol. 1993;119: 215-9.
46. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J Cereb Blood Flow Metab. 1996;16: 578-84.
47. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology. 1994;44: 1747-51.
48. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology. 1995;45: 815-9.
49. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke. 1995;26: 1438-42.
50. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 2001;57: 1428-34.
51. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, Smith CW. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology. 1993;17: 915-23.
52. Simpson PJ, Todd 3rd RF, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988;81: 624-9.
53. Simpson PJ, Todd 3rd RF, Mickelson JK, Fantone JC, Gallagher KP, Lee KA, et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation. 1990;81: 226-37.
54. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol. 1994;35: 458-63.
55. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25: 869-75.
56. Bednar MM, Wright SD, Raymond-Russell SJ, Kohut JJ, Gross CE. IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Neurol Res. 1996;18: 171-5.
57. Colditz I, Zwahlen R, Dewald B, Baggiolini M. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. Am J Pathol. 1989;134: 755-60.
58. Huber AR, Kunkel SL, Todd 3rd RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science. 1991;254: 99-102.
59. Al-Bahrani A, Taha S, Shaath H, Bakhiet M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res. 2007;4: 31-7.
60. Kostulas N, Pelidou SH, Kivisakk P, Kostulas V, Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke. 1999;30: 2174-9.
61. Wittwer AJ, Carr LS, Zagorski J, Dolecki GJ, Crippes BA, De Larco JE. High-level expression of cytokine-induced neutrophil chemoattractant (CINC) by a metastatic rat cell line: purification and production of blocking antibodies. J Cell Physiol. 1993;156: 421-7.
62. Yamasaki Y, Matsuo Y, Zagorski J, Matsuura N, Onodera H, Itoyama Y, et al. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res. 1997;759: 103-11.
63. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3: 81-8.
64. Buttini M, Appel K, Sauter A, Gebicke-Haerter PJ, Boddeke HW. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience. 1996;71: 1-16.
65. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett. 1996;206: 149-52.
66. Lavine SD, Hofman FM, Zlokovic BV. Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J Cereb Blood Flow Metab. 1998;18: 52-8.
67. Meistrell 3rd ME, Botchkina GI, Wang H, Di Santo E, Cockroft KM, Bloom O, et al. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock. 1997;8: 341-8.
68. Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J, et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 2001;8: 679-86.
69. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44: 223-6.
70. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee SL, Rothlein R, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol. 1990;144: 4604-12.
71. Schneider D, Berrouschot J, Brandt T, Hacke W, Ferbert A, Norris SH, et al. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol. 1998;40: 78-83.
72. Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke. 2001;32: 2665-74.
73. Vuorte J, Lindsberg PJ, Kaste M, Meri S, Jansson SE, Rothlein R, et al. Anti-ICAM-1 monoclonal antibody R6. 5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol. 1999;162: 2353-7.